Ligand Reports First Quarter 2024 Financial Results Conference Call Begins at 4:30 p.m. Eastern Time Today JUPITER, Fla., May 7, 2024 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. “We are pleased to report another quarter of strong f ...

Thanks to the Magnificent Seven, tech stocks have led the Q1 earnings season. In fact, as Sheraz Mian the Director of Zacks Investment Research points out, had it not been for the substantial earnings contribution of the Mag 7, Q1 earnings growth for the rest of the S&P 500 index would be in negative territory.That said, several top-rated Zacks Medical sector stocks are standing out ahead of their Q1 reports on Tuesday, May 7. With now looking like an ideal to invest in their growth, here are three of these ...

AndreyPopovThis is my sixth article on royalty aggregator Ligand Pharmaceuticals (NASDAQ:LGND). My most recent previous Ligand article was 06/2023's "Ligand Pharmaceuticals: The New Ligand ("New Ligand"). In it I rated Ligand as a "Buy". At the time it was selling for $76.42. As I write on 04/21/2024 Ligand currently trades at ~$70.00, down ~8%. I continue to rate Ligand at a "Buy" because of its recent streamlining moves as discussed in this article. I view it as a better investment now because of thes ...

Ligand Pharmaceuticals (LGND) closed the last trading session at $79.92, gaining 10.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $116.33 indicates a 45.6% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $25.11. While the lowest estimate of $95 indicates an 18.9% increase from the current price level, the most optimistic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

The team is extremely excited about the potential for this program. We're in process of building a new standalone company called Pathios Therapeutics that will commercialize ZELSUVMI. Company creation effort is very similar to our prior efforts related to Viking Therapeutics and Primrose Bio. ZELSUVMI operated fully independent of Ligand, but we expect to own a significant equity stake in the business at inception. While we are having discussions with potential strategic licensing partners, we're also makin ...

"2023 was a transformative year for Ligand, both operationally and financially. We refocused the company to be a lean- infrastructure, high-margin business," said Todd Davis, CEO of Ligand. "We enhanced our deal making capabilities with the strengthening of our senior team and opening of a Boston office. These initiatives will help us execute on a larger scale and continue to expand our portfolio through a focus on life science royalty opportunities. We are now well positioned and resourced to close on mult ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From ______ to ______ . Commission File Number: 001-33093 LIGAND PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 3911 Sorrento Valley Boulevard, Suite 110 Washington, D.C. 20549 _____________________________________________________________________ ...

Simon Latimer Moving to slide 4. we will discuss business development and the investment team scale up. One of our key priorities over the last 12 months has been to scale our investment capabilities, including origination, diligence and deal making, to bring more institutional process to the way we originate, negotiate and execute on investments. This requires the best available talent in pharmaceutical investing and deal making. Simon Latimer - Head-Investor Relations Todd Davis - Chief Executive Officer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Per ...